Bone marrow transplantation in patients with acute leukemia.
At least three factors may be responsible for leukemic relapse in patients receiving ABMT: (a) minimal residual disease; (b) leukemic cells reinfused with the graft; and (c) the lack of a graft-versus leukemia effect. Techniques for pharmacological marrow decontamination, clinical result obtained with ABMT and the efficacy of ABMT with mafosfamide purged marrow in patients with acute myelogenous leukemia are reviewed.
Caramatti
C
C
Department of Hematology, University of Parma.
Mangoni
L
L
Carlo-Stella
C
C
Rizzoli
V
V
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D001853:Bone Marrow / Q000187:drug effects; D016026:Bone Marrow Transplantation / Q000379:methods; D003520:Cyclophosphamide / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D012008:Recurrence; D013997:Time Factors; D014182:Transplantation, Autologous
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; C048341:mafosfamide; D003520:Cyclophosphamide